Clinical trials: Hypertrophic Obstructive Cardiomyopathy \(HOCM\)
Cardiomyopathy, Hypertrophic
Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy
Patients with hypertrophic obstructive cardiomyopathy and New York Heart Association Class I-II under stable treatment with mavacamten (at least 12 weeks without change of dosage) and a peak left ventricular outflow tract…
- Trial name
- MavaEnEx (NCT07077005)
- Testing
- Exercise training
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Technical University of Munich
Hypertrophic Cardiomyopathy, Obstructive
Percutaneous Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy in Children
The primary purpose of this study was to demonstrate the safety and efficacy of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) in children and assessed its performance and functional outcomes in the…
- Trial name
- NCT06540183
- Testing
- Percutaneous intramyocardial septal radiofrequency ablation
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Xijing Hospital
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Real-World Effectiveness of Mavacamten in Canada
The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM)…
- Trial name
- MAVEN (NCT06338202)
- Testing
- Mavacamten
- Where
- Canada
- Volunteers
- 115 people
- Sponsor
- Bristol-Myers Squibb
Friedreich Ataxia, Cardiomyopathy, Secondary
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).
- Trial name
- SUNRISE-FA 2 (NCT07721025)
- Testing
- LX2006, Usual Care
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Lexeo Therapeutics
Hypertrophic Obstructive Cardiomyopathy
First-in-Man Early Feasibility Study for Transcatheter HOCM Septal Ablation
Transcatheter Intra-septal RF ablation system (TIRA catheter with its supplemental devices) to treat hypertrophic obstructive cardiomyopathy.
- Trial name
- NCT04770142
- Testing
- TIRA catheter
- Where
- 9 sites in South Korea
- Volunteers
- 5 people
- Sponsor
- Tau-MEDICAL Co., Ltd.
HOCM, Hypertrophic Obstructive Cardiomyopathy, LVOTO - Left Ventricular Outflow Tract Obstruction
Reverse Remodeling After PTSMA in Severe But Asymptomatic LVOT Obstruction
Patients with HOCM and severe LVOT obstruction can remain asymptomatic while significant cellular and structural changes of the heart (adverse remodeling) may occur preceding heart failure and rhythm disorders.
- Conditions
- HOCM, Hypertrophic Obstructive Cardiomyopathy, LVOTO - Left Ventricular Outflow Tract Obstruction, Remodeling, Ventricular
- Trial name
- RASTA (NCT04230551)
- Testing
- PTSMA
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- St. Antonius Hospital
Non-obstructive Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy
Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease, is a cause of disability including heart failure, atrial fibrillation, and sudden death, with an annual mortality varying from 1% to 6%.
- Trial name
- CPAPandHCM (NCT01631006)
- Testing
- CPAP
- Where
- Brazil
- Volunteers
- 26 people
- Sponsor
- University of Sao Paulo
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
This study aims to evaluate whether, under a treatment strategy primarily guided by left ventricular ejection fraction (LVEF), dose up-titration in adult patients with symptomatic obstructive hypertrophic cardiomyopathy who have…
- Trial name
- NCT07807384
- Testing
- Mavacamten
- Volunteers
- 115 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Non-obstructive Hypertrophic Cardiomyopathy
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.
- Trial name
- IMPROVE-HCM (NCT04826185)
- Testing
- IMB-1018972
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 67 people
- Sponsor
- Imbria Pharmaceuticals, Inc.
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Ademetionine in Obstructive Hypertrophic Cardiomyopathy
This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM).
- Trial name
- NCT07367724
- Testing
- Ademetionine 1,4-Butanedisulfonate
- Where
- 3 sites in China
- Volunteers
- 44 people
- Sponsor
- China National Center for Cardiovascular Diseases
Cardiomyopathy, Hypertrophic
Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy
DDD pacing improves symptoms and relieves LV outflow tract (LVOT) obstruction in most patients with hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT00001530
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Obstructive Hypertrophic Cardiomyopathy
Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy
This prospective, multicenter, single-arm objective performance criteria trial is designed to assess the efficacy and safety of the Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) procedure in the treatment of…
- Trial name
- NCT06224621
- Testing
- Percutaneous Endocardial Septal Radiofrequency Ablation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- China National Center for Cardiovascular Diseases
Hypertrophic Obstructive Cardiomyopathy (HOCM)
CArdiac Desynchronization In Obstructive HCM, CARDIO-HCM
The purpose of this study is to evaluate the benefit of the optimal pacing configuration, including the possibility of biventricular or left ventricular pacing, in hypertrophic obstructive cardiomyopathy patients.
- Trial name
- CARDIO-HCM (NCT01332162)
- Testing
- Biventricular pacing, No Pacing
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Hospital Clinic of Barcelona